WO2009089399A3 - Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection - Google Patents

Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection Download PDF

Info

Publication number
WO2009089399A3
WO2009089399A3 PCT/US2009/030513 US2009030513W WO2009089399A3 WO 2009089399 A3 WO2009089399 A3 WO 2009089399A3 US 2009030513 W US2009030513 W US 2009030513W WO 2009089399 A3 WO2009089399 A3 WO 2009089399A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
toll
receptor
methods
coreceptor
Prior art date
Application number
PCT/US2009/030513
Other languages
French (fr)
Other versions
WO2009089399A2 (en
Inventor
Jinzhong Zhang
Keith Wayne Ward
Toan Vo
Original Assignee
Bausch & Lomb Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Incorporated filed Critical Bausch & Lomb Incorporated
Publication of WO2009089399A2 publication Critical patent/WO2009089399A2/en
Publication of WO2009089399A3 publication Critical patent/WO2009089399A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions for treating or controlling degeneration of at least a component of the human optic nerve system comprise an antagonist to a toll-like receptor, a coreceptor thereof, or a combination thereof. The compositions can also include an anti- inflammatory medicament. Such compositions can be administered to provide neuroprotection to a patient suffering from an ocular disease, such as glaucoma, AMD, DR, or retinitis pigmentosa.
PCT/US2009/030513 2008-01-10 2009-01-09 Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection WO2009089399A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2015908P 2008-01-10 2008-01-10
US61/020,159 2008-01-10

Publications (2)

Publication Number Publication Date
WO2009089399A2 WO2009089399A2 (en) 2009-07-16
WO2009089399A3 true WO2009089399A3 (en) 2009-10-08

Family

ID=40790420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030513 WO2009089399A2 (en) 2008-01-10 2009-01-09 Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection

Country Status (1)

Country Link
WO (1) WO2009089399A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
ITUB20169937A1 (en) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF PIGMENTAL RETINITIS
WO2017214378A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
EP3707262A1 (en) 2017-11-08 2020-09-16 President and Fellows of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412641A2 (en) * 1989-06-22 1991-02-13 Teijin Limited Use of vitamin D in retinopathy
US20030216431A1 (en) * 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2006102408A2 (en) * 2005-03-22 2006-09-28 Children's Hospital Medical Center Methods and compositions for the modulation of immune responses and autoimmune diseases
WO2006120696A2 (en) * 2005-02-21 2006-11-16 Rajeev Raut An improved pharmaceutical composition
WO2007109813A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007133800A2 (en) * 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
WO2008062288A2 (en) * 2006-11-23 2008-05-29 Cadila Pharmaceuticals Limited Poly-tlr antagonist
WO2009006141A2 (en) * 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
WO2009015107A1 (en) * 2007-07-20 2009-01-29 Yeda Research And Development Co. Ltd. Modulation of toll-like receptors for controlling neurogenesis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412641A2 (en) * 1989-06-22 1991-02-13 Teijin Limited Use of vitamin D in retinopathy
US20030216431A1 (en) * 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2006120696A2 (en) * 2005-02-21 2006-11-16 Rajeev Raut An improved pharmaceutical composition
WO2006102408A2 (en) * 2005-03-22 2006-09-28 Children's Hospital Medical Center Methods and compositions for the modulation of immune responses and autoimmune diseases
WO2007109813A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007133800A2 (en) * 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
WO2008062288A2 (en) * 2006-11-23 2008-05-29 Cadila Pharmaceuticals Limited Poly-tlr antagonist
WO2009006141A2 (en) * 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
WO2009015107A1 (en) * 2007-07-20 2009-01-29 Yeda Research And Development Co. Ltd. Modulation of toll-like receptors for controlling neurogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEUBAUER A S ET AL: "Detecting chloroquine retinopathy: electro-oculogram versus colour vision.", THE BRITISH JOURNAL OF OPHTHALMOLOGY JUL 2003, vol. 87, no. 7, July 2003 (2003-07-01), pages 902 - 908, XP002534831, ISSN: 0007-1161 *
SUN SIQUAN ET AL: "TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders", INFLAMMATION & ALLERGY DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS, vol. 6, no. 4, 1 December 2007 (2007-12-01), pages 223 - 235, XP009108385, ISSN: 1871-5281 *

Also Published As

Publication number Publication date
WO2009089399A2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2011014587A3 (en) Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2008054544A3 (en) Method for delivery across the blood brain barrier
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2010141761A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
WO2009105690A3 (en) Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
WO2011084550A3 (en) Delivery and extraction devices
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PL1979355T3 (en) Spiro imidazole derivatives as ppar modulators
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2009046446A3 (en) Dendrimers for sustained release of compounds
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
MX2012004848A (en) Tricyclic heterocyclic compounds.
DK2319517T3 (en) APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION
WO2011157416A3 (en) Transdermal administration of memantine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700673

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09700673

Country of ref document: EP

Kind code of ref document: A2